Only 66% of FDA-approved biosimilars launched, with Humira & Enbrel facing limited competition despite biosimilars priced ...

Merck, Bristol Myers Squibb, Sanofi and Roche — were eager to position themselves as fully prepared for whatever may come ...

The grow­ing drug dis­count pro­gram for low-in­come Amer­i­cans, known as the 340B pro­gram, has “trans­paren­cy and ...

San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents.

Morgan Cheatham joins Breyer Capital as healthcare head, discusses AI virtual labs' potential in drug discovery.

During Thursday’s first-quarter earnings call, Chris Boerner made his strongest comments yet that Bristol Myers intends to be ...

Lotte Biologics, Ypsomed, PCI Pharma, Samsung Biologics, Catalent & Ferring share manufacturing updates: new ADC services, ...

Tempus AI expands deals with AstraZeneca and Pathos for $200M, Avidicure raises $50M seed round, Bioxodes reports Phase 2a ...

Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for ...

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported ...

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China.